Ignite Creation Date:
2024-05-05 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00267696
Status:
COMPLETED
Last Update Posted:
2015-04-30
First Post:
2005-12-19
Brief Title:
Study of GemcitabineCarboplatinBevacizumab to Treat Ovarian Fallopian Tube or Primary Peritoneal Cancer
Sponsor:
Ohio State University Comprehensive Cancer Center
Organization:
Ohio State University Comprehensive Cancer Center
Organization Data
Organization:
Ohio State University Comprehensive Cancer Center
Class:
OTHER
Study ID:
OSU-05070
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
Larry Copeland
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Ohio State University Comprehensive Cancer Center
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Eli Lilly and Company | INDUSTRY |
| Genentech Inc | INDUSTRY |